Monte Rosa Therapeutics (GLUE) Financials

$19.39 -0.42 (-2.12%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$18.88 -0.52 (-2.66%)

As of 05/8/2026 05:54 PM Eastern

Annual Income Statements for Monte Rosa Therapeutics

This table shows Monte Rosa Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-44	-74	-108	-136	-73	-39
Consolidated Net Income / (Loss)	-36	-74	-109	-135	-73	-39
Net Income / (Loss) Continuing Operations	-44	-74	-109	-135	-73	-39
Total Pre-Tax Income	-36	-74	-109	-135	-70	-40
Total Operating Income	-28	-73	-112	-143	-81	-54
Total Gross Profit	0.00	0.00	0.00	0.00	76	124
Total Revenue	0.00	0.00	0.00	0.00	76	124
Operating Revenue	-	-	-	0.00	76	124
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	28	73	112	143	157	178
Selling, General & Admin Expense	4.01	16	27	32	35	36
Research & Development Expense	24	57	85	111	122	142
Total Other Income / (Expense), net	-7.87	-1.08	3.88	8.30	11	14
Interest & Investment Income	0.01	0.05	3.76	9.33	11	13
Other Income / (Expense), net	-7.88	-1.12	0.12	-0.91	0.42	1.54
Income Tax Expense	-	-	0.00	0.34	2.57	-1.10
Basic Earnings per Share	($23.65)	-	($2.30)	($2.63)	($0.98)	($0.46)
Weighted Average Basic Shares Outstanding	1.52M	25.00M	47.23M	51.40M	73.91M	83.07M
Diluted Earnings per Share	($23.65)	-	($2.30)	($2.63)	($0.98)	($0.46)
Weighted Average Diluted Shares Outstanding	1.52M	25.00M	47.23M	51.40M	73.91M	83.07M
Weighted Average Basic & Diluted Shares Outstanding	1.52M	25.00M	49.36M	50.15M	61.51M	80.02M

This table shows Monte Rosa Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-35	-35	-32	-30	-24	12	47	-12	-27	-47	-45
Consolidated Net Income / (Loss)	-35	-33	-32	-30	-24	13	47	-12	-27	-46	-45
Net Income / (Loss) Continuing Operations	-35	-33	-32	-30	-24	13	47	-12	-27	-46	-45
Total Pre-Tax Income	-35	-33	-32	-30	-24	16	48	-11	-30	-46	-44
Total Operating Income	-37	-35	-35	-33	-27	13	44	-16	-33	-50	-50
Total Gross Profit	0.00	-	1.06	4.70	9.22	61	85	23	13	2.78	4.21
Total Revenue	0.00	-	1.06	4.70	9.22	61	85	23	13	2.78	4.21
Operating Revenue	0.00	-	1.06	4.70	9.22	61	85	23	13	2.78	4.21
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	37	35	36	37	36	48	41	39	46	52	54
Selling, General & Admin Expense	8.66	7.73	8.99	9.28	8.13	8.78	8.70	8.10	9.07	11	10
Research & Development Expense	28	27	27	28	28	39	32	31	37	42	44
Total Other Income / (Expense), net	2.25	1.59	3.06	2.58	2.74	2.60	3.67	4.46	2.72	3.64	5.58
Interest & Investment Income	2.23	2.37	2.44	2.64	2.89	2.60	3.44	3.07	2.75	3.69	5.59
Other Income / (Expense), net	0.03	-0.65	0.62	-0.05	-0.15	0.00	0.23	1.39	-0.03	-0.05	-0.01
Income Tax Expense	0.17	-0.02	0.08	0.25	0.07	2.16	0.82	1.20	-3.18	0.06	0.05
Basic Earnings per Share	($0.70)	($0.57)	($0.53)	($0.43)	($0.29)	$0.27	$0.57	($0.15)	($0.33)	($0.55)	($0.45)
Weighted Average Basic Shares Outstanding	49.81M	51.40M	60.16M	71.23M	82.01M	73.91M	82.15M	82.19M	82.40M	83.07M	99.88M
Diluted Earnings per Share	($0.70)	($0.57)	($0.53)	($0.43)	($0.29)	$0.27	$0.57	($0.15)	($0.33)	($0.55)	($0.45)
Weighted Average Diluted Shares Outstanding	49.81M	51.40M	60.16M	71.23M	82.01M	73.91M	82.96M	82.19M	82.40M	83.07M	99.88M
Weighted Average Basic & Diluted Shares Outstanding	50.08M	50.15M	50.51M	61.37M	-	61.51M	61.51M	61.76M	65.12M	80.02M	84.48M

This table details how cash moves in and out of Monte Rosa Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	34	309	-291	72	96	-94
Net Cash From Operating Activities	-23	-59	-92	-44	42	-23
Net Cash From Continuing Operating Activities	-23	-59	-92	-44	42	-23
Net Income / (Loss) Continuing Operations	-36	-74	-109	-135	-73	-39
Consolidated Net Income / (Loss)	-36	-74	-109	-135	-73	-39
Depreciation Expense	0.54	2.13	3.75	6.22	8.12	8.36
Non-Cash Adjustments To Reconcile Net Income	8.03	6.18	14	13	15	8.58
Changes in Operating Assets and Liabilities, net	4.26	6.29	-2.13	72	91	-1.11
Net Cash From Investing Activities	-3.39	-9.65	-219	89	-44	-102
Net Cash From Continuing Investing Activities	-3.39	-9.65	-219	89	-44	-102
Purchase of Property, Plant & Equipment	-3.39	-9.73	-13	-19	-3.99	-4.70
Purchase of Investments	-	0.00	-384	-103	-230	-377
Sale and/or Maturity of Investments	-	0.00	178	211	190	280
Net Cash From Financing Activities	60	378	20	27	99	30
Net Cash From Continuing Financing Activities	60	378	20	27	99	30
Repurchase of Common Equity	-0.44	-0.23	-0.36	-0.12	-0.64	-0.36
Issuance of Debt	-	-	-	0.00	47	0.00
Issuance of Common Equity	0.00	238	20	25	51	24
Other Financing Activities, net	0.00	0.15	0.78	2.61	1.59	6.46

This table details how cash moves in and out of Monte Rosa Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	12	69	-28	9.10	17	99	-146	-9.03	139	-78	30
Net Cash From Operating Activities	-25	30	-38	-28	-21	129	-45	-35	100	-43	-37
Net Cash From Continuing Operating Activities	-25	30	-38	-28	-21	129	-45	-35	100	-43	-37
Net Income / (Loss) Continuing Operations	-35	-33	-32	-30	-24	13	47	-12	-27	-46	-45
Consolidated Net Income / (Loss)	-35	-33	-32	-30	-24	13	47	-12	-27	-46	-45
Depreciation Expense	1.83	1.85	1.90	2.06	2.10	2.06	2.05	2.13	2.10	2.09	2.03
Non-Cash Adjustments To Reconcile Net Income	4.10	3.34	4.80	3.41	3.19	3.77	4.21	4.16	3.90	-3.68	12
Changes in Operating Assets and Liabilities, net	4.37	58	-13	-2.93	-2.43	110	-99	-29	122	4.72	-6.86
Net Cash From Investing Activities	36	14	9.85	-61	38	-31	-100	25	38	-65	-261
Net Cash From Continuing Investing Activities	36	14	9.85	-61	38	-31	-100	25	38	-65	-261
Purchase of Property, Plant & Equipment	-1.66	-1.69	-1.38	-2.02	-0.40	-0.18	-1.59	-1.70	-0.65	-0.77	-1.87
Purchase of Investments	-7.81	-28	-56	-74	-32	-68	-138	-19	-66	-154	-332
Sale and/or Maturity of Investments	45	44	67	15	71	37	39	46	105	89	73
Net Cash From Financing Activities	1.10	25	0.25	98	0.02	0.61	0.01	0.37	0.35	30	328
Net Cash From Continuing Financing Activities	1.10	25	0.25	98	0.02	0.61	0.01	-	0.71	30	328
Repurchase of Common Equity	-	-0.12	0.00	-0.64	-	-	0.00	-	-	-0.36	0.00
Issuance of Debt	-	-	0.00	47	-	-	-	-	-	-	324
Issuance of Common Equity	-	25	0.00	51	-	-	0.00	-	-	24	0.00
Other Financing Activities, net	1.10	0.29	0.25	0.42	0.02	0.61	0.01	-	0.71	5.73	4.04

This table presents Monte Rosa Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	49	366	342	304	439	449
Total Current Assets	44	349	276	236	377	393
Cash & Equivalents	42	346	55	128	224	130
Short-Term Investments	-	0.00	208	104	148	247
Accounts Receivable	-	0.00	7.66	0.51	0.17	4.60
Prepaid Expenses	1.89	2.60	4.44	3.29	5.12	4.48
Other Current Assets	-	-	-	-	0.00	7.00
Plant, Property, & Equipment, net	4.62	12	27	34	29	26
Total Noncurrent Assets	1.16	5.34	39	34	32	29
Other Noncurrent Operating Assets	1.16	5.34	39	34	32	29
Total Liabilities & Shareholders' Equity	49	366	342	304	439	449
Total Liabilities	30	19	71	125	216	216
Total Current Liabilities	29	17	26	47	157	64
Accounts Payable	9.60	17	22	26	36	30
Current Deferred Revenue	-	-	0.00	18	117	30
Other Current Liabilities	20	0.00	3.13	3.16	3.71	4.40
Total Noncurrent Liabilities	1.07	2.18	45	78	59	151
Noncurrent Deferred Revenue	-	-	0.00	32	16	111
Noncurrent Employee Benefit Liabilities	1.07	2.18	1.53	2.71	3.70	5.27
Other Noncurrent Operating Liabilities	-	0.00	44	43	39	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-49	348	271	179	223	233
Total Preferred & Common Equity	49	348	271	179	223	233
Preferred Stock	-	-	0.00	0.00	0.00	0.00
Total Common Equity	-49	348	271	179	223	233
Common Stock	0.41	472	504	548	665	714
Retained Earnings	-48	-122	-231	-366	-439	-477
Accumulated Other Comprehensive Income / (Loss)	-1.06	-2.02	-1.75	-2.72	-3.36	-3.83

This table presents Monte Rosa Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	279	252	267	344	315	393	360	460	736
Total Current Assets	208	183	199	278	251	332	299	402	678
Cash & Equivalents	47	59	100	109	126	79	69	208	160
Short-Term Investments	156	119	93	153	117	248	221	183	506
Accounts Receivable	1.15	0.29	0.60	9.84	0.60	1.41	2.37	4.97	4.61
Prepaid Expenses	3.88	4.14	5.54	5.85	8.43	4.80	6.50	5.59	6.72
Other Current Assets	-	-	-	-	-	-	-	-	0.00
Plant, Property, & Equipment, net	35	35	34	33	31	29	29	28	28
Total Noncurrent Assets	35	34	34	33	32	32	31	30	30
Other Noncurrent Operating Assets	35	34	34	33	32	32	31	30	30
Total Liabilities & Shareholders' Equity	279	252	267	344	315	393	360	460	736
Total Liabilities	65	68	114	119	110	118	92	214	215
Total Current Liabilities	19	23	41	42	42	59	42	61	71
Accounts Payable	16	20	18	19	19	23	19	32	33
Current Deferred Revenue	-	-	20	20	19	33	18	25	33
Other Current Liabilities	2.67	2.88	3.35	3.47	3.65	3.87	4.09	4.24	4.48
Total Noncurrent Liabilities	46	45	73	77	68	59	50	153	143
Noncurrent Deferred Revenue	-	-	29	34	25	17	8.06	112	104
Noncurrent Employee Benefit Liabilities	1.51	1.45	2.57	2.61	2.82	3.96	4.56	4.74	5.26
Other Noncurrent Operating Liabilities	44	44	42	41	40	38	37	36	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	214	185	153	225	205	275	268	246	522
Total Preferred & Common Equity	214	185	153	225	205	275	268	246	522
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	214	185	153	225	205	275	268	246	522
Common Stock	513	519	553	656	660	670	675	680	1,048
Retained Earnings	-298	-333	-398	-428	-452	-392	-404	-431	-522
Accumulated Other Comprehensive Income / (Loss)	-1.64	-1.46	-2.69	-2.67	-2.32	-3.33	-3.37	-3.25	-4.75

This table displays calculated financial ratios and metrics derived from Monte Rosa Therapeutics' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	46,505,914.00	48,399,056.00	50,081,023.00	-	65,117,761.00
DEI Adjusted Shares Outstanding	0.00	46,505,914.00	48,399,056.00	50,081,023.00	-	65,117,761.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1.59	-2.24	-2.72	-	-0.60
Growth Metrics	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-20	-51	-79	-100	-57	-38
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-55.97%	-25.47%	-16.28%
Earnings before Interest and Taxes (EBIT)	-36	-74	-112	-144	-81	-53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-72	-109	-138	-73	-44
Valuation Ratios	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-75	-85	-40	39	-43
Efficiency Ratios	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-23	1.44	7.63	-53	-149	-144
Increase / (Decrease) in Invested Capital	0.00	24	6.18	-61	-96	5.17
Book Value per Share	($32.12)	$7.47	$5.61	$3.58	$3.02	$3.58
Tangible Book Value per Share	($32.12)	$7.47	$5.61	$3.58	$3.02	$3.58
Total Capital	19	348	271	179	223	233
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-42	-346	-264	-232	-372	-377
Capital Expenditures (CapEx)	3.39	9.65	13	19	3.99	4.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-27	-14	-13	-43	-152	-48
Debt-free Net Working Capital (DFNWC)	14	332	250	190	220	329
Net Working Capital (NWC)	14	332	250	190	220	329
Net Nonoperating Expense (NNE)	16	23	30	35	16	0.68
Net Nonoperating Obligations (NNO)	-42	-346	-264	-232	-372	-377
Total Depreciation and Amortization (D&A)	0.54	2.13	3.75	6.22	8.12	8.36
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.96)	$0.00	($2.63)	($0.98)	($0.46)
Adjusted Weighted Average Basic Shares Outstanding	0.00	46.63M	47.23M	51.40M	73.91M	83.07M
Adjusted Diluted Earnings per Share	$0.00	($2.96)	$0.00	($2.63)	($0.98)	($0.46)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	46.63M	47.23M	51.40M	73.91M	83.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	($2.96)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	25.00M	49.36M	50.15M	61.51M	80.02M
Normalized Net Operating Profit after Tax (NOPAT)	-20	-51	-79	-100	-57	-38
Debt Service Ratios	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Monte Rosa Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	49,383,711.00	50,081,023.00	50,154,073.00	50,512,019.00	61,372,824.00	-	61,509,821.00	61,509,821.00	61,759,350.00	65,117,761.00	80,015,667.00
DEI Adjusted Shares Outstanding	49,383,711.00	50,081,023.00	50,154,073.00	50,512,019.00	61,372,824.00	-	61,509,821.00	61,509,821.00	61,759,350.00	65,117,761.00	80,015,667.00
DEI Earnings Per Adjusted Shares Outstanding	-0.70	-0.69	-0.64	-0.60	-0.38	-	0.76	-0.20	-0.44	-0.72	-0.57
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7,882.05%	394.01%	38.54%	-	-95.04%
EBITDA Growth	-28.68%	-6.61%	2.68%	14.66%	29.99%	144.76%	242.82%	60.70%	-25.76%	-	-203.66%
EBIT Growth	-30.46%	-8.77%	0.43%	12.32%	27.78%	136.63%	228.96%	56.68%	-23.70%	-	-213.04%
NOPAT Growth	-30.34%	-7.31%	-2.01%	12.30%	28.24%	145.89%	276.91%	52.35%	-24.31%	-	-180.93%
Net Income Growth	-27.70%	-8.02%	0.22%	13.84%	31.60%	140.41%	246.66%	59.44%	-13.50%	-	-194.92%
EPS Growth	-20.69%	0.00%	18.46%	39.44%	58.57%	147.37%	207.55%	65.12%	-13.79%	-	-178.95%
Operating Cash Flow Growth	-19.93%	223.68%	-63.06%	-9.65%	15.02%	335.05%	-19.20%	-25.04%	578.37%	-	17.86%
Free Cash Flow Firm Growth	60.80%	225.79%	202.44%	187.94%	273.63%	194.76%	99.76%	-202.51%	253.65%	-	8.45%
Invested Capital Growth	-66.37%	-797.04%	-465.96%	-454.50%	-707.39%	-180.67%	-26.11%	40.02%	-295.93%	-	-183.43%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	341.26%	96.29%	558.06%	40.04%	-72.69%	-44.95%	-	51.38%
EBITDA Q/Q Growth	2.21%	4.11%	3.67%	5.54%	19.77%	161.31%	207.40%	-125.99%	-156.74%	-	-0.70%
EBIT Q/Q Growth	0.94%	3.87%	3.33%	4.75%	18.40%	148.75%	240.37%	-132.00%	-133.01%	-	-0.56%
NOPAT Q/Q Growth	0.68%	5.69%	-0.24%	6.60%	18.73%	160.32%	286.40%	-125.16%	-112.00%	-	-0.64%
Net Income Q/Q Growth	0.84%	4.68%	3.86%	5.19%	21.28%	156.32%	248.92%	-126.22%	-120.26%	-	3.54%
EPS Q/Q Growth	1.41%	18.57%	7.02%	18.87%	32.56%	193.10%	111.11%	-126.32%	-120.00%	-	18.18%
Operating Cash Flow Q/Q Growth	2.44%	219.95%	-228.79%	27.24%	24.39%	714.09%	-135.29%	23.68%	389.25%	-	13.12%
Free Cash Flow Firm Q/Q Growth	51.49%	360.99%	-25.95%	-6.20%	-4.22%	343.05%	-49.82%	-148.14%	430.44%	-	246.04%
Invested Capital Q/Q Growth	-42.89%	-979.16%	24.06%	7.03%	2.14%	-306.25%	65.88%	55.78%	-545.91%	-	-0.18%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
EBITDA Margin	0.00%	0.00%	-3,047.93%	-652.50%	-266.68%	24.84%	54.54%	-51.91%	-242.08%	-	-1,140.45%
Operating Margin	0.00%	0.00%	-3,284.49%	-695.25%	-287.84%	21.44%	51.85%	-67.06%	-258.26%	-	-1,188.46%
EBIT Margin	0.00%	0.00%	-3,226.22%	-696.38%	-289.50%	21.45%	52.12%	-61.07%	-258.49%	-	-1,188.65%
Profit (Net Income) Margin	0.00%	0.00%	-3,004.51%	-645.58%	-258.89%	22.16%	55.20%	-53.01%	-212.10%	-	-1,057.08%
Tax Burden Percent	100.49%	99.93%	100.26%	100.84%	100.30%	86.13%	98.28%	110.81%	89.50%	-	100.12%
Interest Burden Percent	93.97%	93.70%	92.89%	91.93%	89.16%	119.95%	107.77%	78.34%	91.68%	-	88.83%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	13.87%	1.72%	0.00%	0.00%	-	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Return on Equity (ROE)	-55.88%	-60.07%	-68.28%	-59.51%	-61.23%	-36.15%	2.88%	9.81%	9.28%	-	-32.62%
Cash Return on Invested Capital (CROIC)	-721.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-11.92%	-12.88%	-15.29%	4.37%	25.19%	-30.89%	-121.11%	-	-90.39%
Return on Assets (ROA)	0.00%	0.00%	-11.10%	-11.94%	-13.67%	4.51%	26.68%	-26.82%	-99.38%	-	-80.39%
Return on Common Equity (ROCE)	-55.88%	-60.07%	-68.28%	-59.51%	-61.23%	-36.15%	2.88%	9.81%	9.28%	-	-32.62%
Return on Equity Simple (ROE_SIMPLE)	-72.01%	0.00%	-88.70%	0.00%	0.00%	0.00%	2.24%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	-26	-24	-24	-23	-19	11	43	-11	-23	-35	-35
NOPAT Margin	0.00%	0.00%	-2,299.14%	-486.68%	-201.49%	18.47%	50.96%	-46.94%	-180.78%	-	-831.92%
Net Nonoperating Expense Percent (NNEP)	-3.99%	-3.57%	-3.53%	-3.21%	-2.52%	0.74%	1.39%	-0.51%	-1.26%	-	-1.91%
Return On Investment Capital (ROIC_SIMPLE)	-	-13.61%	-16.04%	-10.17%	-9.04%	5.02%	15.73%	-4.06%	-9.39%	-14.93%	-6.71%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	844.45%	197.70%	88.18%	14.47%	10.25%	34.90%	71.00%	-	241.69%
R&D to Revenue	0.00%	0.00%	2,540.04%	597.55%	299.65%	64.09%	37.90%	132.16%	287.27%	-	1,046.77%
Operating Expenses to Revenue	0.00%	0.00%	3,384.49%	795.25%	387.84%	78.56%	48.15%	167.06%	358.26%	-	1,288.46%
Earnings before Interest and Taxes (EBIT)	-37	-36	-34	-33	-27	13	44	-14	-33	-50	-50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-34	-32	-31	-25	15	46	-12	-31	-48	-48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.28	1.58	2.32	0.84	1.58	1.91	1.04	1.03	1.86	-	2.52
Price to Tangible Book Value (P/TBV)	1.28	1.58	2.32	0.84	1.58	1.91	1.04	1.03	1.86	-	2.52
Price to Revenue (P/Rev)	0.00	0.00	332.32	32.80	21.72	5.63	1.79	1.56	2.52	-	30.64
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	51.73	11.82	22.86	-	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.93%	8.46%	4.37%	-	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	151.03	0.00	5.55	0.71	0.00	0.00	0.37	-	15.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.60	-	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.57	-	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.17	-	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	1.28	0.00	0.00	0.45	-	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	1.37	0.00	0.00	0.57	-	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Financial Leverage	-0.95	-1.10	-1.07	-1.06	-1.08	-1.50	-1.21	-1.12	-1.40	-	-1.24
Leverage Ratio	1.28	1.43	1.45	1.42	1.45	1.85	1.54	1.43	1.72	-	1.42
Compound Leverage Factor	1.20	1.34	1.35	1.31	1.30	2.21	1.66	1.12	1.57	-	1.26
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Altman Z-Score	0.53	0.04	0.06	-0.27	0.34	0.66	1.67	1.47	1.02	-	3.51
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.09	5.07	4.82	6.56	6.03	2.40	5.61	7.16	6.54	-	9.54
Quick Ratio	7.91	5.00	4.69	6.42	5.83	2.37	5.53	7.00	6.45	-	9.44
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	36	27	25	24	107	54	-26	86	-40	58
Operating Cash Flow to CapEx	-1,489.21%	1,754.53%	-2,757.59%	-1,373.24%	-5,261.65%	70,449.18%	-2,866.54%	-2,048.38%	15,426.73%	-	-2,000.48%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.02	0.05	0.20	0.48	0.51	0.47	-	0.08
Accounts Receivable Turnover	0.00	0.00	0.77	1.05	33.69	223.07	158.77	29.15	65.30	-	14.28
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Fixed Asset Turnover	0.00	0.00	0.03	0.17	0.45	2.39	5.03	5.71	6.15	-	1.49
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Days Sales Outstanding (DSO)	0.00	0.00	475.29	348.46	10.83	1.64	2.30	12.52	5.59	-	25.57
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	475.29	348.46	10.83	1.64	2.30	12.52	5.59	-	25.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	6.05	-53	-40	-38	-37	-149	-51	-23	-145	-144	-144
Invested Capital Turnover	0.00	0.00	-0.07	-0.43	-0.98	-0.75	-3.49	-5.93	-1.99	-	-0.44
Increase / (Decrease) in Invested Capital	-12	-61	-51	-48	-43	-96	-11	15	-109	5.17	-93
Enterprise Value (EV)	58	51	161	-73	83	54	-41	-13	66	-	650
Market Capitalization	237	283	354	189	325	426	285	277	458	-	1,316
Book Value per Share	$3.70	$3.58	$3.04	$4.45	$3.35	$3.02	$4.47	$4.36	$3.98	$3.58	$6.52
Tangible Book Value per Share	$3.70	$3.58	$3.04	$4.45	$3.35	$3.02	$4.47	$4.36	$3.98	$3.58	$6.52
Total Capital	185	179	153	225	205	223	275	268	246	233	522
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-178	-232	-193	-262	-242	-372	-326	-291	-391	-377	-666
Capital Expenditures (CapEx)	1.66	1.69	1.38	2.02	0.40	0.18	1.59	1.70	0.65	0.77	1.87
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-43	-35	-27	-33	-152	-53	-33	-51	-48	-60
Debt-free Net Working Capital (DFNWC)	160	190	158	236	210	220	273	258	340	329	607
Net Working Capital (NWC)	160	190	158	236	210	220	273	258	340	329	607
Net Nonoperating Expense (NNE)	9.01	8.85	7.51	7.46	5.29	-2.24	-3.61	1.41	4.00	11	9.48
Net Nonoperating Obligations (NNO)	-178	-232	-193	-262	-242	-372	-326	-291	-391	-377	-666
Total Depreciation and Amortization (D&A)	1.83	1.85	1.90	2.06	2.10	2.06	2.05	2.13	2.10	2.09	2.03
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-3,303.48%	-462.88%	-217.83%	-200.54%	-33.24%	-18.53%	-28.03%	-	-139.01%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	14,825.47%	4,090.09%	1,399.44%	291.57%	171.21%	144.74%	187.49%	-	1,412.03%
Net Working Capital to Revenue	0.00%	0.00%	14,825.47%	4,090.09%	1,399.44%	291.57%	171.21%	144.74%	187.49%	-	1,412.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.70)	($0.57)	($0.53)	($0.43)	($0.29)	$0.27	$0.57	($0.15)	($0.33)	($0.55)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	49.81M	51.40M	60.16M	71.23M	82.01M	73.91M	82.15M	82.19M	82.40M	83.07M	99.88M
Adjusted Diluted Earnings per Share	($0.70)	($0.57)	($0.53)	($0.43)	($0.29)	$0.27	$0.57	($0.15)	($0.33)	($0.55)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	49.81M	51.40M	60.16M	71.23M	82.01M	73.91M	82.96M	82.19M	82.40M	83.07M	99.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.08M	50.15M	50.51M	61.37M	0.00	61.51M	61.51M	61.76M	65.12M	80.02M	84.48M
Normalized Net Operating Profit after Tax (NOPAT)	-26	-24	-24	-23	-19	11	43	-11	-23	-35	-35
Normalized NOPAT Margin	0.00%	0.00%	-2,299.14%	-486.68%	-201.49%	18.47%	50.96%	-46.94%	-180.78%	-	-831.92%
Pre Tax Income Margin	0.00%	0.00%	-2,996.71%	-640.21%	-258.12%	25.72%	56.17%	-47.84%	-236.98%	-	-1,055.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Augmented Payout Ratio	-0.05%	-0.09%	0.00%	-0.58%	-0.63%	-0.88%	10.42%	0.00%	0.00%	-	-0.27%

Financials Breakdown Chart

Key Financial Trends

Monte Rosa Therapeutics (GLUE) has shown liquidity improvements in 2025 from financing activity and asset sales, but continues to burn cash and post GAAP losses in most quarters. Below are the key trends pulled from the last four years of quarterly statements.

Q3 2025 operating cash flow turned positive (~$100.4M), marking a notable quarterly improvement in cash generation.
Financing activity provided meaningful liquidity in 2025, with sizable net cash inflows in multiple quarters (e.g., about $97.7M in Q2 2025 and $29.6M in Q4 2025).
Cash and cash equivalents rose to roughly $208M by Q3 2025, giving a substantial liquidity cushion for ongoing R&D and operations.
Asset sales of investments contributed to liquidity, including sizable maturities/sales in several quarters (e.g., $89.36M in Q3 2025; $46.05M in Q2 2025; $37.25M in Q4 2024).
No preferred stock and a solid common equity base, with total common equity around $275M by Q3 2025, supporting a flexible capitalization base.
Revenue is volatile and not consistently growing, with operating revenue fluctuating across quarters (notable spike in some periods followed by declines).
Net income to common shareholders has been negative in most recent quarters, for example about -$46.7M (Q4 2025), -$26.9M (Q3 2025), -$12.3M (Q2 2025), and -$31.9M (Q1 2025).
Sizable R&D expense remains a major outflow, such as around $42.0M in Q4 2025 and $36.7M in Q3 2025, typical for a biotech pipeline but contributing to cash burn.
Investing cash outflows are substantial, driven by large purchases of investments as part of liquidity management (ongoing outflows across quarters).
Recurring cash burn from operations persists, with negative net cash from continuing operating activities in multiple quarters (e.g., -$43.0M in Q4 2025; -$34.7M in Q2 2025; -$45.5M in Q1 2025).
Bottom-line profitability remains negative on a GAAP basis, with net income attributable to common shareholders negative in the latest quarters (e.g., -$46.7M in Q4 2025 and -$26.9M in Q3 2025).

05/09/26 01:17 AM ETAI Generated. May Contain Errors.

Monte Rosa Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Monte Rosa Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 5 years, Monte Rosa Therapeutics' net income has ranged from -$135.35 million in 2023 to -$35.88 million in 2020, and is currently -$38.63 million as of their latest financial filing in 2025. Check out Monte Rosa Therapeutics' forecast to explore projected trends and price targets.

Monte Rosa Therapeutics' total operating income in 2025 was -$54.21 million, based on the following breakdown:

Total Gross Profit: $123.67 million
Total Operating Expenses: $177.88 million

Over the last 5 years, Monte Rosa Therapeutics' total revenue changed from $0.00 in 2020 to $123.67 million in 2025, a change of 12,367,200,000.0%.

Monte Rosa Therapeutics' total liabilities were at $215.60 million at the end of 2025, a 0.1% decrease from 2024, and a 610.6% increase since 2020.

In the past 5 years, Monte Rosa Therapeutics' cash and equivalents has ranged from $41.70 million in 2020 to $346.07 million in 2021, and is currently $129.88 million as of their latest financial filing in 2025.

Over the last 5 years, Monte Rosa Therapeutics' book value per share changed from -32.12 in 2020 to 3.58 in 2025, a change of -111.1%.

Related Companies

Financial statements for NASDAQ:GLUE last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Financials

Financials Breakdown Chart

Key Financial Trends

Monte Rosa Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monte Rosa Therapeutics (GLUE) Financials

Annual Income Statements for Monte Rosa Therapeutics

Quarterly Income Statements for Monte Rosa Therapeutics

Annual Cash Flow Statements for Monte Rosa Therapeutics

Quarterly Cash Flow Statements for Monte Rosa Therapeutics

Annual Balance Sheets for Monte Rosa Therapeutics

Quarterly Balance Sheets for Monte Rosa Therapeutics

Annual Metrics And Ratios for Monte Rosa Therapeutics

Quarterly Metrics And Ratios for Monte Rosa Therapeutics

Financials Breakdown Chart

Key Financial Trends

Monte Rosa Therapeutics Financials - Frequently Asked Questions

When does Monte Rosa Therapeutics' financial year end?

How has Monte Rosa Therapeutics' net income changed over the last 5 years?

What is Monte Rosa Therapeutics' operating income?

How has Monte Rosa Therapeutics' revenue changed over the last 5 years?

How much debt does Monte Rosa Therapeutics have?

How much cash does Monte Rosa Therapeutics have?

How has Monte Rosa Therapeutics' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools